New journal devoted to hot button issue: childhood obesity

Share this article:
New journal devoted to hot button issue: childhood obesity
New journal devoted to hot button issue: childhood obesity

First Lady Michelle Obama's recent announcement of a campaign to end childhood obesity was not lost on medical publisher Mary Ann Liebert, Inc., which will roll out a new journal, Childhood Obesity, in June 2010.

The journal represents a re-branding of Liebert's Obesity and Weight Management, which will be folded into the new title. Vicki Cohn, executive VP and managing editor at Liebert, said the decision to focus the journal on childhood obesity was "not an advertising thing," but reflects "the enormous problem" of childhood obesity. "It's a hot subject," said Cohn.

The re-branded, peer-reviewed Childhood Obesity will offer original articles, perspectives from opinion leaders, safety and efficacy treatment regimens and case reports, among other features, to physicians, nurses and other healthcare professionals, according to a company statement.  

Cohn said Liebert has "maintained steady advertising sales" across its journal portfolio, which includes flagship Genetic Engineering and Biotechnology News, ASSAY and Drug Development Technologies, and AIDS Research and Human Retroviruses, among others covering biotechnology, medicine, surgery, nursing and integrative medicine. Liebert titles are primarily subscription-based, said Cohn, adding that the company's journals go out to 140 countries. For 2010, 15 Liebert titles will increase the number of issues published each year, according to the website.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...